Amicus Therapeutics, Inc.

Symbol: FOLD

NASDAQ

9.48

USD

Market price today

  • -18.3613

    P/E Ratio

  • -0.1932

    PEG Ratio

  • 2.81B

    MRK Cap

  • 0.00%

    DIV Yield

Amicus Therapeutics, Inc. (FOLD) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.90%

Operating Profit Margin

-0.19%

Net Profit Margin

-0.38%

Return on Assets

-0.19%

Return on Equity

-1.19%

Return on Capital Employed

-0.13%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Bradley L. Campbell M.B.A.
Full-time employees:517
City:Philadelphia
Address:3675 Market Street
IPO:2007-05-31
CIK:0001178879

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

General Outlook

When we look at how much money they make before expenses, they keep 0.901% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.193%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.380%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.195% return, is a testament to Amicus Therapeutics, Inc.'s adeptness in optimizing resource deployment. Amicus Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.195%. Furthermore, the proficiency of Amicus Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.126% return on capital employed.

Stock Prices

Amicus Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $10.6, while its low point bottomed out at $9.98. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Amicus Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing FOLD liquidity ratios reveals its financial health of the firm. The current ratio of 288.07% gauges short-term asset coverage for liabilities. The quick ratio (222.93%) assesses immediate liquidity, while the cash ratio (147.29%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio288.07%
Quick Ratio222.93%
Cash Ratio147.29%

Profitability Ratios

FOLD profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -37.59% underscores its earnings before tax deductions. The effective tax rate stands at -5.16%, revealing its tax efficiency. The net income per EBT, 100.99%, and the EBT per EBIT, 195.04%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -19.27%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-37.59%
Effective Tax Rate-5.16%
Net Income per EBT100.99%
EBT per EBIT195.04%
EBIT per Revenue-19.27%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.88, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 455.72% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding223
Days of Inventory Outstanding552
Operating Cycle631.60
Days of Payables Outstanding140
Cash Conversion Cycle492
Receivables Turnover4.56
Payables Turnover2.61
Inventory Turnover0.66
Fixed Asset Turnover6.89
Asset Turnover0.51

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.24, and free cash flow per share, -0.26, depict cash generation on a per-share basis. The cash per share value, 0.97, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.17, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.24
Free Cash Flow per Share-0.26
Cash per Share0.97
Operating Cash Flow Sales Ratio-0.17
Free Cash Flow to Operating Cash Flow Ratio1.11
Cash Flow Coverage Ratio-0.17
Short Term Coverage Ratio-8.30
Capital Expenditure Coverage Ratio-9.29
Dividend Paid and Capex Coverage Ratio-9.29

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 50.93%, highlights its total liabilities relative to assets. With a debt-equity ratio of 2.47, we discern the balance between debt and equity financing. The long-term debt to capitalization, 70.77%, and total debt to capitalization, 71.21%, ratios shed light on its capital structure. An interest coverage of -3.18 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio50.93%
Debt Equity Ratio2.47
Long Term Debt to Capitalization70.77%
Total Debt to Capitalization71.21%
Interest Coverage-3.18
Cash Flow to Debt Ratio-0.17
Company Equity Multiplier4.86

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.35, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.51, reflects the portion of profit attributed to each share. The book value per share, 0.54, represents the net asset value distributed per share, while the tangible book value per share, -0.20, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.35
Net Income Per Share-0.51
Book Value Per Share0.54
Tangible Book Value Per Share-0.20
Shareholders Equity Per Share0.54
Interest Debt Per Share1.51
Capex Per Share-0.03

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 21.30%, indicates top-line expansion, while the gross profit growth, 21.86%, reveals profitability trends. EBIT growth, 64.05%, and operating income growth, 64.05%, offer insights into operational profitability progression. The net income growth, 35.92%, showcases bottom-line expansion, and the EPS growth, 37.80%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth21.30%
Gross Profit Growth21.86%
EBIT Growth64.05%
Operating Income Growth64.05%
Net Income Growth35.92%
EPS Growth37.80%
EPS Diluted Growth37.80%
Weighted Average Shares Growth2.11%
Weighted Average Shares Diluted Growth2.11%
Operating Cash Flow Growth58.52%
Free Cash Flow Growth55.07%
10-Year Revenue Growth per Share19015.64%
5-Year Revenue Growth per Share175.49%
3-Year Revenue Growth per Share34.25%
10-Year Operating CF Growth per Share73.79%
5-Year Operating CF Growth per Share85.50%
3-Year Operating CF Growth per Share74.03%
10-Year Net Income Growth per Share55.83%
5-Year Net Income Growth per Share72.66%
3-Year Net Income Growth per Share51.98%
10-Year Shareholders Equity Growth per Share-39.17%
5-Year Shareholders Equity Growth per Share-70.60%
3-Year Shareholders Equity Growth per Share-50.95%
Receivables Growth32.38%
Inventory Growth150.66%
Asset Growth7.42%
Book Value per Share Growth27.48%
Debt Growth-1.56%
R&D Expense Growth-44.92%
SGA Expenses Growth29.21%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 4,386,449,467.85, captures the company's total value, considering both debt and equity. Income quality, 0.46, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 28.06%, indicates the value of non-physical assets, and capex to operating cash flow, 10.77%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value4,386,449,467.85
Income Quality0.46
Research and Development to Revenue38.16%
Intangibles to Total Assets28.06%
Capex to Operating Cash Flow10.77%
Capex to Revenue-1.86%
Capex to Depreciation-94.50%
Stock-Based Compensation to Revenue21.55%
Graham Number2.50
Return on Tangible Assets-27.09%
Graham Net Net-0.80
Working Capital315,372,000
Tangible Asset Value-58,113,000
Net Current Asset Value-134,645,000
Invested Capital2
Average Receivables76,914,000
Average Payables15,266,500
Average Inventory41,756,000
Days Sales Outstanding80
Days Payables Outstanding122
Days of Inventory On Hand482
ROIC-13.34%
ROE-0.95%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 17.38, and the price to book ratio, 17.38, reflect the market's valuation relative to the company's book value. The price to sales ratio, 7.03, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -36.69, and price to operating cash flows, -40.28, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio17.38
Price to Book Ratio17.38
Price to Sales Ratio7.03
Price Cash Flow Ratio-40.28
Price Earnings to Growth Ratio-0.19
Enterprise Value Multiple-27.49
Price Fair Value17.38
Price to Operating Cash Flow Ratio-40.28
Price to Free Cash Flows Ratio-36.69
Price to Tangible Book Ratio26.15
Enterprise Value to Sales10.98
Enterprise Value Over EBITDA-66.85
EV to Operating Cash Flow-63.49
Earnings Yield-3.62%
Free Cash Flow Yield-1.83%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Amicus Therapeutics, Inc. (FOLD) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -18.361 in 2024.

What is the ticker symbol of Amicus Therapeutics, Inc. stock?

The ticker symbol of Amicus Therapeutics, Inc. stock is FOLD.

What is company IPO date?

IPO date of Amicus Therapeutics, Inc. is 2007-05-31.

What is company current share price?

Current share price is 9.480 USD.

What is stock market cap today?

The market cap of stock today is 2807748480.000.

What is PEG ratio in 2024?

The current -0.193 is -0.193 in 2024.

What is the number of employees in 2024?

In 2024 the company has 517.